Financial Results

Home > Investors > News & Updates

News & Updates  

Higher revenue from exports, bulk drugs and Home-Diagnostics businesses fuel Morepen Lab's sales and profitability growth in Q4 FY 2016-17
Outcome of Board Meeting held on 29-04-2017
Notice of Board Meeting and Intimation of Closure of Trading Window
Morepen Labs reports yet another growth-filled quarter-Company’s topline goes up by 23 per cent, backed by a 74% jump in the sales of its bulk drug Montelukast in the Q3 of fiscal 2016-17
Outcome of Board Meeting held on 08-02-2017
Notice of Board Meeting - 08.02.2017
Morepen Labs reports 118 percent jump in Net Profits for the Q2 of FY 2016-17
Outcome of Board Meeting held on 09-11-2016
Notice of Board Meeting to be held on 09.11.2016
Outcome of AGM on 23-09-2016
Voting Results of AGM on 23-09-2016
Addendum to Notice of AGM 2016-17
Outcome of Board Meeting held on 17-09-2016
Notice of AGM 2015-16
Morepen Labs strengthens its position in bulk drugs market for Montelukast and Rosuvastatin
Outcome of Board Meeting held on 09-08-2016
Notice of Board Meeting to be held on 09.08.2016
Morepen Laboratories scores No.1 position globally for its bulk drug Montelukast - 10.05.2016
Notice of Board Meeting to be held on 10.05.2016
Press Release 08-02-2016
Notice of Board Meeting to be held on 08.02.2016
Outcome of Board Meeting 04-11-2015
Press Release 04-11-2015
Scrutinizers Report for the AGM - 18.09.2015.
Notice of AGM 2014-15
Scrutinizer's Report - Poll
Scrutinizer's Report - E-voting
Scrutinizer's Report - Combined
Notice of Board Meeting 29.07.2014
Notice of Record Date dt 29.07.2014